Cambridge, UK, 14th October 2019: Mogrify Ltd (Mogrify), a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date. The funding will support internal cell therapy programs, and the development and out-license of novel IP relating to cell conversions of broad therapeutic interest.
News
Clinical Professionals fully fund and train some of the UK’s brightest life science graduates with the aim of giving back and assisting in the future of the industry talent pool and future skilled professionals.
Reading Scientific Services Ltd (RSSL) secures Enlighted Employer Award in recognition of its exceptional commitment to gender equality in the workplace.
Nadhim Zahawi MP has announced that Stevenage Bioscience Catalyst (SBC) has been successful in its application to become a Life Science Opportunity Zone.
The assessment panel consisted of senior industry life science experts and senior government officials. In a letter to Stevenage Bioscience Catalyst Chief Executive Officer Dr Sally Ann Forsyth, the Minister stated: “l am delighted to tell you that your application has been successful. The panel were impressed by your plans to grow what is already a successful biomedical campus.”
Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247.
Leading Cambridge and international intellectual property (IP) firm Marks & Clerk is to host the Cambridge IP Summit, taking place on Thursday 10 October at the Hilton Hotel, Cambridge.
The event aims to build upon the success of last year’s summit, which brought leading businesses from Cambridge and beyond together to discuss how to protect high-tech innovation.
Westbury, NY – Oct. 2, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has appointed Lori Ball as its chief operating officer (COO). In her new position, Ms. Ball will be responsible for providing leadership and strategic direction on operational and business decisions, including growth planning, business and organizational development, risk management, and quality control.